Jubilant Pharmova Limited (NSE:JUBLPHARMA)
India
· Delayed Price · Currency is INR 1,073.70
+6.20 (0.58%)
Dec 5, 2025, 3:29 PM IST
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2005 - 2019 |
| Radiopharma | 33.88B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Radiopharma Growth | 12.88% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Contract Development and Manufacturing Organisation - Sterile Injectables | 12.72B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Contract Development and Manufacturing Organisation - Sterile Injectables Growth | 13.84% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Contract Research, and Development and Manufacturing Organisation | 11.51B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Contract Research, and Development and Manufacturing Organisation Growth | 5.31% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Allergy Immunotherapy | 7.01B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Allergy Immunotherapy Growth | 3.35% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Generics | 6.85B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Generics Growth | -11.53% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Management Services | 372.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Management Services Growth | -2.87% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Proprietary Novel Drugs | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Proprietary Novel Drugs Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Contract Research and Development | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Contract Research and Development Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2005 - 2019 |
| Americas and Europe | 65.94B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas and Europe Growth | 9.67% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of the World | 4.28B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of the World Growth | -14.17% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| India | 2.13B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| India Growth | 10.78% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Global | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|